{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:02:20Z","timestamp":1763179340732,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jchf.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T15:46:05Z","timestamp":1638978365000},"page":"139-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can We Manage Presymptomatic TTR\u00a0V142I Related Risk?"],"prefix":"10.1016","volume":"10","author":[{"given":"Michael F.","family":"Murray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jchf.2021.10.009_bib1","first-page":"49","article-title":"Genomic screening identifies individuals at high risk for hereditary transthyretin amyloidosis","volume":"11","author":"Soper","year":"2021","journal-title":"J\u00a0Pers Med"},{"issue":"22","key":"10.1016\/j.jchf.2021.10.009_bib3","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino Ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2021.10.009_bib4","first-page":"129","article-title":"Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in Black adults","volume":"10","author":"Coniglio","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"30","key":"10.1016\/j.jchf.2021.10.009_bib5","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jchf.2021.10.009_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.18.01398","article-title":"Validation of Mayo Clinic Staging System for light chain amyloidosis with high-sensitivity troponin","volume":"37","author":"Kumar","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921005059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177921005059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:01Z","timestamp":1761973201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177921005059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213177921005059"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2021.10.009","relation":{},"ISSN":["2213-1779"],"issn-type":[{"type":"print","value":"2213-1779"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can We Manage Presymptomatic TTR\u00a0V142I Related Risk?","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2021.09.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}